Developmental biology

New international research center to drive future stem cell-derived medicines

Retrieved on: 
Friday, December 17, 2021
Faculty, Murdoch Children's Research Institute, University of Copenhagen Faculty of Health and Medical Sciences, ReNew, Ventricular septal defect, Research, Leiden University Medical Center, Stem cell, Medicine, Chronic kidney disease, Center, Rebuild, Science, Resolve, Research institute, Organoid, University of Copenhagen, B cell, Institute, Rewrite, CEO, Gene editing, Patient, 3D, Ulcerative colitis, Tissue, Novo Nordisk Foundation Center for Protein Research, Disease, University, Novo Nordisk Foundation, Developmental biology, Partnership, Diabetes, Gene, Parkinson's disease, Translation, Pharmaceutical industry, Medical imaging, Vaccine, Health

This is exactly what the new international stem cell research center aims to achieve.

Key Points: 
  • This is exactly what the new international stem cell research center aims to achieve.
  • "Building on the stem cell research excellence that exists within all partner institutions, the Center will reach a critical mass that is required for translating fundamental discoveries into stem cell medicine.
  • Murdoch Children's Research Institute is a world-leader in children's health research with a specific strategic initiative within stem cell medicine.
  • The research activities within the Novo Nordisk Foundation Center for Stem Cell Medicine will begin in the start of January 2022.

New international research center to drive future stem cell-derived medicines

Retrieved on: 
Friday, December 17, 2021
Faculty, Murdoch Children's Research Institute, University of Copenhagen Faculty of Health and Medical Sciences, ReNew, Ventricular septal defect, Research, Leiden University Medical Center, Stem cell, Medicine, Chronic kidney disease, Center, Rebuild, Science, Resolve, Research institute, Organoid, University of Copenhagen, B cell, Institute, Rewrite, CEO, Gene editing, Patient, 3D, Ulcerative colitis, Tissue, Novo Nordisk Foundation Center for Protein Research, Disease, University, Novo Nordisk Foundation, Developmental biology, Partnership, Diabetes, Gene, Parkinson's disease, Translation, Pharmaceutical industry, Medical imaging, Vaccine, Health

This is exactly what the new international stem cell research center aims to achieve.

Key Points: 
  • This is exactly what the new international stem cell research center aims to achieve.
  • "Building on the stem cell research excellence that exists within all partner institutions, the Center will reach a critical mass that is required for translating fundamental discoveries into stem cell medicine.
  • Murdoch Children's Research Institute is a world-leader in children's health research with a specific strategic initiative within stem cell medicine.
  • The research activities within the Novo Nordisk Foundation Center for Stem Cell Medicine will begin in the start of January 2022.

Anavo Therapeutics Announces the Appointment of Charles McDermott as Chairman of the Board

Retrieved on: 
Thursday, December 9, 2021
Biotechnology, Pharmaceutical, Health, Optometry, NDA, Business development, Associate, Therapy, Business, D, Growth, Drug discovery, Biochemistry, Leadership, MA, Allergan, BA, Â, Industry, Developmental biology, Lymphatic system, Director, CEO, Board, Molecular biology, University of California, Santa Cruz, University, Genetics, DeCODE genetics, University of California, Santa Barbara, Doctor of Philosophy, Biology, MBA, Pharmaceutical industry

Anavo Therapeutics , a global leader in unlocking the full therapeutic potential of human phosphatase biology, today announced the appointment of Charles McDermott as Chairman of the Board of Directors.

Key Points: 
  • Anavo Therapeutics , a global leader in unlocking the full therapeutic potential of human phosphatase biology, today announced the appointment of Charles McDermott as Chairman of the Board of Directors.
  • Mr. McDermott currently serves as the Chairman, CEO and President of Primmune Therapeutics.
  • Mr. McDermott further strengthens Anavos existing Board, which includes: Therese Maria Liechtenstein, M Ventures; Simone Botti, INKEF Capital; Sakae Asanuma, Taiho Ventures; Deborah Dumont, Biqube Ventures; Birgit Zech, Anavo Therapeutics; and Gerhard Mller, Anavo Therapeutics.
  • Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades.

Susan Tousi Joins Vizgen as Scientific Advisor

Retrieved on: 
Tuesday, November 30, 2021
Science, Health, Oncology, Research, Harvard University, Journal of Cellular and Molecular Medicine, Genomics, CEO, National academy, Central Waqf Council, Cell, Neuroscience, Technology, Disease, Industry, Wyss Institute, Bionics, Health, SAB, Kodak, Engineering, Developmental biology, G.H. Raisoni Department of Microbiology and Biotechnology, Running, Department, COVID-19, Invention, Hewlett-Packard, Howard Hughes Medical Institute, Wyss Institute for Biologically Inspired Engineering, Twitter, Research, Fortune, Diversity, Social media, Efficiency, Hospital, Bioinspiration, Data visualization, Drug discovery, Assistant, LinkedIn, Molecular medicine, Infection, Harvard Medical School, Growth, National Academy of Engineering, Management, Medical imaging, MERSCOPE, Vizgen, MERSCOPE, VIZGEN

In addition to Vizgens current scientific consultants, Susan Tousi, Chief Commercial Officer at Illumina, will join the SAB.

Key Points: 
  • In addition to Vizgens current scientific consultants, Susan Tousi, Chief Commercial Officer at Illumina, will join the SAB.
  • The Vizgen Scientific and Technical Advisory Board brings together a group of world-class leaders in life sciences technology to address the growing demand for single-cell spatial genomics research, said Terry Lo, President and CEO of Vizgen.
  • Susan Tousi brings to Vizgens SAB more than 25 years of R&D and business leadership experience at Fortune 100 technology companies, most recently in the life sciences industry.
  • Currently at Illumina , Susan oversees global sales, commercial operations, and commercial strategy and enablement.

Matt Posard Joins Vizgen Board of Directors

Retrieved on: 
Wednesday, November 17, 2021
Technology, Research, Genetics, Software, Biotechnology, Health, General Health, Other Science, Science, Efficiency, Industry, Genomics, Data visualization, Health, General manager, Neuroscience, LinkedIn, CEO, Disease, Infection, Senior, Emerging market, Social media, Running, Board, Therapy, History, Board of directors, Drug discovery, Developmental biology, DNA, Cell, Management, Medical imaging, MERSCOPE, Vizgen, MERSCOPE, VIZGEN

Vizgen , the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announces the appointment of Matt Posard to their Board of Directors.

Key Points: 
  • Vizgen , the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announces the appointment of Matt Posard to their Board of Directors.
  • As the first outside director for Vizgen, Matt will provide guidance to expand market strategies and corporate growth.
  • Matt joins our board with an impressive 30 years of commercial and general management expertise in the life sciences industry, combined with a remarkable history of success, said Terry Lo, President and CEO of Vizgen.
  • I am deeply honored to be joining Vizgens Board of Directors, says Matt.

Dovetail Genomics Launches Boston Epigenetics Society to Accelerate Vital Epigenetics and Epitranscriptomics Research, with Additional Societies in Several Metropolitan Cities in Development

Retrieved on: 
Wednesday, November 10, 2021
Biotechnology, Health, Genetics, University, Education, Constellation, Harvard University, Sanofi, Chromatin, Industry, Therapy, Genetics, Method, Broad Institute, CEO, EST, Technology, NGS, Harvard Medical School, Society, Beth Israel Deaconess Medical Center, Research, Astellas Pharma, University of Massachusetts Medical School, Biology, Massachusetts General Hospital, Genome, Genomics, Developmental biology, AstraZeneca, Ageing, Pharmaceutical industry

The Society brings together both academic and industry partners in the greater Boston area and beyond, all sharing a passion for epigenetics.

Key Points: 
  • The Society brings together both academic and industry partners in the greater Boston area and beyond, all sharing a passion for epigenetics.
  • A critical component of Dovetails mission is to enable cutting-edge science and research in the field of epigenetics, said Todd Dickinson, CEO of Dovetail Genomics.
  • The inaugural meeting of the Boston Epigenetics Society takes place virtually on Tuesday, November 16 from 10am - 11am EST, and features guest speaker David A. Sinclair, Ph.D.
  • Additional Societies for major metropolitan regions with a concentration of epigenetic and epitranscriptomic innovation are currently under development.

Akoya Biosciences Announces Founding Members of First-of-its-Kind Imaging Innovators (I²) Network

Retrieved on: 
Tuesday, November 2, 2021
Massachusetts Institute of Technology, I2, Biology, Research, Lists of diseases, University, Map, Disease, Goal, Massachusetts, Immunology, Wellcome Sanger Institute, Security (finance), U.S. Securities and Exchange Commission, Harvard University, Beth Israel, Developmental biology, Terminology, Infection, RNA, Center, CODEX, Brain, Bachelor of Engineering, Software, Forward-looking statement, Virology, Neuroscience, CEO, Growth, Program, Solution, Health, Nasdaq, MIT, Spatial organization, Cerebral cortex, GLOBE, Doctor of Philosophy, HIV disease progression rates, Microscope, Medical imaging, Pharmaceutical industry

MARLBOROUGH, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company®, today announced the first members of the Akoya Imaging Innovators (I²) Network, a collaboration of pioneering scientists from world-class research organizations, with ambitions to advance the field of spatial biology.

Key Points: 
  • MARLBOROUGH, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company, today announced the first members of the Akoya Imaging Innovators (I ) Network , a collaboration of pioneering scientists from world-class research organizations, with ambitions to advance the field of spatial biology.
  • Akoya established the program to encourage leaders in diverse fields of research to pursue disruptive applications within spatial phenotyping.
  • Akoya is excited to foster transformative research and applications for spatial phenotyping through the I2 Network," said Brian McKelligon, CEO at Akoya Biosciences.
  • Network members will also have first access to pre-release CODEX tools and may influence future product strategy.

ProFuse Technology received $1.25M from Fresh Start FoodTech Incubator

Retrieved on: 
Monday, October 18, 2021
Leadership, Technology, Program, Solution, 50, Physics, Climate change, Cancer, Growth, Fresh Start, Love Profusion, Weizmann Institute of Science, Interferon beta-1a, Food industry, Brain, Parity, OurCrowd, Artificial intelligence, Fresh Start (detergent), Research, Yissum Research Development Company of the Hebrew University, Tempo, CEO, Science and technology in Asia, Patent, Developmental biology, Meat, Cell fusion, Income, CTO, Agriculture

The company's founders' extensive academic record is now geared to advance one of today's most promising and highly-invested foodtech fields cultured meat.

Key Points: 
  • The company's founders' extensive academic record is now geared to advance one of today's most promising and highly-invested foodtech fields cultured meat.
  • Dr. Tammy Meiron, Fresh Start FoodTech Incubator CTO: "ProFuse responds to one of the most significant challenges concerning cultured meat companies today, and is an important enabling technology.
  • Dr. Opher Shapira, CEO, Yeda (Weizmann's technology transfer company): "ProFuse is yet another promising foodtech company coming out of the Weizmann Institute of Science.
  • Fresh Start FoodTech Incubator was established in early 2020 in Kiryat Shmone, as part of the Israeli Innovation Authority's incubators' program, and as a significant part of the evolving foodtech cluster of the Eastern Galilee.

Vizgen Appoints Dale Levitzke as Senior VP Global Sales and Support

Retrieved on: 
Monday, October 18, 2021
Biotechnology, Pharmaceutical, Genetics, Health, NanoString Technologies, University of California, San Diego, Leadership, Harvard University, Social media, Senior, LinkedIn, Genetics, Growth, Gene expression, Molecular biology, Marketing, Market Access Program, Illumina, Inc., Efficiency, Baylor College of Medicine, VP, Disease, Health, MIT, Biology, Neuroscience, Infection, Global Sales Law Project, University, CEO, Broad Institute, Twitter, NASDAQ, La Trobe University, Research, NASU Institute of Molecular Biology and Genetics, Genomics, Developmental biology, Drug discovery, Acquisition, Support, Management

Vizgen , the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has announced the appointment of Dale Levitzke as Senior Vice President Global Sales and Support.

Key Points: 
  • Vizgen , the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has announced the appointment of Dale Levitzke as Senior Vice President Global Sales and Support.
  • His immediate focus will be fostering the growth of the Global Sales and Global Service teams to support worldwide commercial endeavors.
  • Dale joins Vizgen with almost 20 years experience in the sales and marketing of diagnostics and genomics tools, with a track record of driving dramatic commercial growth.
  • As VP of Worldwide Sales at NanoString Inc. (NASDAQ: NSTG), he specialized in developing global sales channels and strategies from the ground up.

DGAP-News: Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

Retrieved on: 
Thursday, October 14, 2021
Leadership, Corporate development, Business development, MBA, Crohn's disease, Private Securities Litigation Reform Act, Ulcerative colitis, Security (finance), Corporation, NEW, Metabolism, Economics, Primary sclerosing cholangitis, SVB Leerink, SEC, Multiple sclerosis, Clinical trial, Patient, Colby College, Biology, Degenerative disease, Nature, University, U.S. Securities and Exchange Commission, Annual report, DHODH, Psoriasis, Drug development, Risk, Therapy, Developmental biology, COVID-19, Vaccine

NEW YORK, October 14, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the appointment of Patrick Walsh as Chief Business Officer, effective today.

Key Points: 
  • NEW YORK, October 14, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the appointment of Patrick Walsh as Chief Business Officer, effective today.
  • "Patrick is a seasoned business development executive who has spent his career helping to successfully build a number of public biopharmaceutical companies.
  • He brings to Immunic extensive leadership in building companies through strategic partnerships and non-dilutive funding," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • Mr. Walsh was previously in Corporate Development at AVEO Oncology, during which time he worked on all aspects of business development.